AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson's disease [Yahoo! Finance]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Yahoo! Finance
AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson's disease, was well tolerated with no attributed serious adverse events in all 11 patients at 18 months, meeting the primary objective Based on the safety and efficacy results presented, a Phase II trial (REGENERATE PD) has been developed and is expected to begin enrolling in the U.S., EU, and UK later this year Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, on Sunday April 14 presented results from the 18-month Phase Ib clinical trial for AB-1005, an investigational gene therapy for treating patients with Parkinson's disease (PD). The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA. The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen. Eleven p
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN) [Yahoo! Finance]Yahoo! Finance
- Seed Paper Bags Bloom as Eco-Conscious Consumers Drive Market to $213.2 Million by 2034 | Future Market Insights, Inc. [Yahoo! Finance]Yahoo! Finance
- Missouri House backs legal shield for weedkiller maker facing thousands of cancer-related lawsuits [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Missouri House backs legal shield for weedkiller maker facing thousands of cancer-related lawsuits [Yahoo! Finance]Yahoo! Finance
- Judge slashes $857 mln Monsanto verdict to $438 mln in PCBs case [Reuters]Reuters